Huntington Disease Breakthrough:

Huntington Disease Breakthrough:

68

+100%-

Huntington Disease Breakthrough: New Potential Therapy That Restores Motor Function Being Planned for Clinical Trial
ScienceDaily (Feb. 13, 2012) — Medical researchers at the University of Alberta have discovered a promising new therapy for Huntington disease that restores lost motor skills and may delay or stop the progression of the disease, says researcher Simonetta Sipione. The therapy is based on lab model tests and, because it uses a molecule already in clinical trials for other diseases, it could be used in a trial for Huntington disease within the next two years.

“We didn’t expect to see such dramatic changes after administering this therapy,” says Sipione, the principal investigator “We expected to see improvement, but not complete restoration of motor skills. When we saw this, we were jumping with excitement in the lab. This is very promising and should give hope to those with Huntington disease. It’s a treatment that deserves to go to clinical trials because it could have huge potential.”

People with this inherited brain disorder — characterized by a mutant protein that triggers brain cell death, loss of motor and cognitive skills and eventually death — have slightly lower levels of a brain molecule called GM1. When U of A medical researchers restored GM1 to normal levels in lab models with the disease, motor skills in the lab models returned to normal within days, says Sipione, a researcher in the Department of Pharmacology and the Centre for Neuroscience, both within the faculty of medicine and dentistry. Her team’s research was recently published in the peer-reviewed journal Proceedings of the National Academy of Sciences.

The researchers used GM1 molecules in the lab tests that were both naturally and synthetically produced. This same molecule has been used in clinical trials for the treatment of Parkinson’s and other neurodegenerative diseases, so a small first-stage clinical trial that uses GM1 for Huntington disease could happen relatively quickly.

Stakeholders are still working out where the trial would take place, but the research team involved is hoping it will be at the U of A and discussions are underway to secure the participation of a University of Alberta Hospital neurologist.

During the research stage, Sipione’s team gave lab models the GM1 molecule therapy for four weeks. During the first two weeks after the treatment finished, the lab models still had normal motor function. But after that, motor function started to decline, returning to pre-treatment levels by the end of the fourth week; a potential treatment with this molecule would involve repeated applications over the long-term, says Sipione.

READ MORE

Fonte:ScienceDaily



Copyright: All rights of any text or trademarks mentioned in the article are reserved to their respective owners.

AICH ROMA ONLUS